BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...
BioCentury | Apr 13, 2021
Product Development

FDA’s ‘pause’ could lead to narrowed indication for J&J COVID-19 vaccine

FDA’s non-binding decision to recommend a “pause” in the use of Johnson & Johnson’s COVID-19 vaccine was among the least strenuous measures it could have taken in response to adverse event reports. The action, which...
BioCentury | Apr 13, 2021
Deals

Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering.  Shareholders of the Fred Hutchinson Cancer Research Center...
BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

A study from Guardant Health Inc. (NASDAQ:GH), Amgen Inc. (NASDAQ:AMGN) and academic collaborators showed Guardant’s plasma cell-free DNA (cfDNA)-based Guardant360 CDx test had an 81.5% positive percent agreement and 100% negative percent agreement with a...
BioCentury | Apr 12, 2021
Product Development

COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

Regeneron reported Phase III data Monday showing subcutaneous REGEN-COV met the primary endpoint of preventing symptomatic COVID-19 in the study’s two populations, and the company plans to request an EUA...
BioCentury | Apr 12, 2021
Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

Agenus’ latest clinical data for AGEN1181 support the idea that Fc engineering can expand the population of patients who respond to checkpoint inhibitors.  While many companies are searching for the...
BioCentury | Apr 12, 2021
Product Development

Carisma adds support for CAR macrophage platform with preclinical data

Carisma is boosting confidence in its CAR macrophage platform ahead of its first clinical readout with preclinical data supporting the cell therapy’s differentiated activity against solid tumors. ...
BioCentury | Apr 12, 2021
Product Development

Sanofi sees early signs that its Synthorx acquisition could pay off with IL-2 data

Sanofi took another step in its oncology pipeline rebuild with the first clinical evidence that a cornerstone program of its oncology pipeline — precision engineered IL-2 therapy THOR-717 -- may be...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
Items per page:
1 - 10 of 10967
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...
BioCentury | Apr 13, 2021
Product Development

FDA’s ‘pause’ could lead to narrowed indication for J&J COVID-19 vaccine

FDA’s non-binding decision to recommend a “pause” in the use of Johnson & Johnson’s COVID-19 vaccine was among the least strenuous measures it could have taken in response to adverse event reports. The action, which...
BioCentury | Apr 13, 2021
Deals

Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering.  Shareholders of the Fred Hutchinson Cancer Research Center...
BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

A study from Guardant Health Inc. (NASDAQ:GH), Amgen Inc. (NASDAQ:AMGN) and academic collaborators showed Guardant’s plasma cell-free DNA (cfDNA)-based Guardant360 CDx test had an 81.5% positive percent agreement and 100% negative percent agreement with a...
BioCentury | Apr 12, 2021
Product Development

COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

Regeneron reported Phase III data Monday showing subcutaneous REGEN-COV met the primary endpoint of preventing symptomatic COVID-19 in the study’s two populations, and the company plans to request an EUA...
BioCentury | Apr 12, 2021
Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

Agenus’ latest clinical data for AGEN1181 support the idea that Fc engineering can expand the population of patients who respond to checkpoint inhibitors.  While many companies are searching for the...
BioCentury | Apr 12, 2021
Product Development

Carisma adds support for CAR macrophage platform with preclinical data

Carisma is boosting confidence in its CAR macrophage platform ahead of its first clinical readout with preclinical data supporting the cell therapy’s differentiated activity against solid tumors. ...
BioCentury | Apr 12, 2021
Product Development

Sanofi sees early signs that its Synthorx acquisition could pay off with IL-2 data

Sanofi took another step in its oncology pipeline rebuild with the first clinical evidence that a cornerstone program of its oncology pipeline — precision engineered IL-2 therapy THOR-717 -- may be...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
Items per page:
1 - 10 of 10967